Related Experiment Video
Updated: May 2, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases
Emel Canbay1, Yutaka Yonemura1, Bjorn Brucher1
11 NPO HIPEC ISTANBUL, Akkavak Sokak No: 4/2 Nisantasi, Istanbul 34365, Turkey ; 2 Ethica Incirli Hospital, Bakirkoy, Istanbul 34144, Turkey ; 3 NPO to support Peritoneal Dissemination Treatment, 1-26, Harukimotomachi, Kishiwada City, Osaka 596-8522, Japan ; 4 Department of General Surgery, Kusatsu General Hospital, Yabase 1660, Kusatsu, Japan ; 5 Department of General Surgery, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-Cho, Kishiwada City, Osaka 596-8522, Japan ; 6 Department of Peritoneal Surface Malignancy, Bon Secours Cancer Institute, Richmond VA 23226, USA ; 7 Deparment of General Surgery, Yonsei University College of Medicine, Seoul, South Korea ; 8 Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, NW, POB North Tower 3900 Washington, DC 20010, USA.
Abstract:
Advanced gastric cancer (GC) has been recognized as lethal disease when peritoneal metastases (PM) occurred. There is no standard treatment for advanced GC with PM. Until 1980s, the therapeutic arena for these patients had remained stagnant, with no therapeutic approach having shown a survival gain in GC with PM. However, cytoreductive surgery (CRS) with peritonectomy procedures and intraperitoneal chemotherapy (IPC) promising new combined therapeutic approach to achieve disease control for GC with PM. The recent publications changed the GC with PM treatment landscape by providing an evidence that CRS and IPC led to prolongation in overall survival (OS). This review will provide an overview of the evolving role of CRS and IPC in the management of advanced GC with PM in the current era.
Insights
Cytoreductive surgery (CRS) combined with intraperitoneal chemotherapy (IPC) offers a new treatment approach for advanced gastric cancer (GC) with peritoneal metastases (PM). This combination therapy has shown improved overall survival (OS) for patients previously lacking effective options.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Advanced gastric cancer (GC) with peritoneal metastases (PM) is a lethal condition with historically limited treatment options.
- No standard treatment provided survival benefits for GC with PM until recent advancements.
Purpose of the Study:
- To review the evolving role of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) in managing advanced GC with PM.
- To highlight the impact of CRS and IPC on patient outcomes in the current era.
Main Methods:
- Review of recent publications and clinical evidence.
- Analysis of the combined therapeutic approach of CRS and IPC.
Main Results:
- Cytoreductive surgery (CRS) with peritonectomy procedures and intraperitoneal chemotherapy (IPC) represents a promising combined therapeutic strategy.
- Recent evidence indicates that CRS and IPC can lead to prolonged overall survival (OS) in patients with GC and PM.
Conclusions:
- CRS and IPC have significantly altered the treatment landscape for advanced GC with PM.
- This combined approach offers a new avenue for disease control and improved survival for patients with peritoneal metastases.
Related Concept Videos
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:28Esophageal Perforation-II: Clinical Manifestations and Management
Clinical Manifestations: